AN2 Therapeutics
inhaled first and only approved lung disease drug is associated with a high discontinuation rate and increased adverse events versus soc therapy alone pivotal study convert results convert study parameter control efficacy culture converted by month safety withdrawn from study upper respiratory adverse events an therapeutics | AN2 Therapeutics
Company
Deck Type
Sector
Industry
Deck date
August 2022
Slide
11 of 25
Similar slides by AN2 Therapeutics
See diffirences between slides (animation)
IPO
March 2022
inhaled first and only approved lung disease drug is associated with a high discontinuation rate and increased adverse events versus soc therapy alone pivotal study convert results convert study parameter control efficacy culture converted by month safety withdrawn from study upper respiratory adverse events boxed warnings associated with an increased risk of respiratory conditions hypersensitivity pneumonitis bronchospasm exacerbation of underlying lung disease and hemoptysis that have led to hospitalizations in some cases other common side effects dysphonia cough upper airway irritation pain fatigue diarrhea and nausea an therapeutics | AN2 Therapeutics
Related slides by other companies
DICE Therapeutics
Investor Presentation
March 2023
demonstrated a favorable safety and tolerability profile | DICE Therapeutics
Kymera
Investor Presentation
June 2023
adverse events related to study drug occurring in patient | Kymera
Kymera
Results
December 2022
adverse events related to study drug occurring in patient | Kymera
ATAI
Investor Presentation
October 2022
was well tolerated with no dose limiting toxicities identified up to the highest dose of given every hours for days there were no serious adverse events reported nor discontinuations due to adverse events and both single and multiple ascending dose sad and mad regimens showed only mild adverse events that were comparable to placebo treated subjects no evidence of sedation or other side effects at any doses tested dose dependent increase in frontal beta power was demonstrated in subjects receiving but not with placebo providing evidence of target engagement and mechanism of action these results show potential use for as a clinically superior treatment for generalized anxiety disorder gad compared to and combination pharmacodynamic effect along lower incidence severity shows favorable profile | ATAI
Other recent decks by AN2 Therapeutics
See all presentations (2 decks)
IPO
March 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io